

# Letter to Editor: Prophylactic Use of Nonsteroidal Anti-Inflammatory Drugs after Cataract Surgery and Corneal Melt

We read with a great interest the report by Ashena *et al.* of an 84-year-old diabetic female who developed corneal melting 5 days after cataract surgery, where the cause was identified as topical ketorolac drops (Acular®, Allergan Laboratories, Dublin, Ireland) given as prophylaxis against pseudophakic cystoid macular edema (CME).<sup>1</sup> This patient had undergone uneventful first eye cataract surgery, but developed corneal melting in her second eye when given ketorolac in addition to topical dexamethasone/tobramycin drops (Tobradex®, Alcon Laboratories, Geneva, Switzerland). Unfortunately, despite corneal gluing and amniotic membrane graft, the eye could not be salvaged and required permanent subtotal tarsorrhaphy.

The authors are to be commended on a thorough literature review. Corneal melting secondary to topical nonsteroidal anti-inflammatory drugs (NSAIDs) has been widely reported with diclofenac (Voltarol®), ketorolac (Acular®), and bromfenac (Yellox®). Cabourne *et al.* looked at 970 diabetic patients at Moorfields given dexamethasone/neomycin (Maxitrol®, Alcon Laboratories, Dublin, Ireland) and ketorolac after routine cataract surgery, finding 13 patients developed keratopathy, with 5 corneal melts and 1 perforation and endophthalmitis.<sup>2</sup> After this, the routine use of ketorolac and Maxitrol® was discontinued, and separate dexamethasone (Maxidex®, Alcon Laboratories, Dublin, Ireland), chloramphenicol, and ketorolac given routinely to diabetic patients undergoing cataract surgery. To our knowledge, there has been only one case of corneal melt with the use of this regimen over the last 6 years at Moorfields, where circa 20,000 cataract procedures are performed annually.

Diabetics are at increased risk of pseudophakic CME, and this risk increases with the severity of retinopathy.<sup>3</sup> Using topical NSAIDs alongside topical steroids after surgery reduces this risk.<sup>4</sup> Given the well-reported risks of prescribing topical NSAIDs alongside neomycin or tobramycin, we caution against the use of this combination in diabetic patients, who likely have some degree of neurotrophic keratopathy. We recommend the use of NSAIDs alongside Maxidex and chloramphenicol from the prevention of CME in all diabetics. Those with preexisting diabetic macular edema should receive concurrent intravitreal dexamethasone injection (Ozurdex®, Allergan Laboratories, Dublin, Ireland), as this commonly gets worse with cataract surgery.<sup>5</sup> Should macular edema develop in those without it preoperatively and fail to settle with topical therapy, treating with intravitreal dexamethasone is a safe and effective treatment option.

## Financial support and sponsorship

Nil.

## Conflicts of interest

There are no conflicts of interest.

Zaid Shalchi<sup>1</sup>, Romesh Angunawela<sup>2</sup>, Robin Hamilton<sup>2</sup>

<sup>1</sup>Royal Berkshire NHS Foundation Trust, Reading, United Kingdom, <sup>2</sup>Moorfields Eye Hospital, London, United Kingdom

**Address for correspondence:** Zaid Shalchi, Royal Berkshire NHS Foundation Trust, London Road, Reading RG1 5AN, United Kingdom. E-mail: zshalchi@gmail.com

**Submitted:** 31-Mar-2022;

**Accepted:** 26-Jun-2022;

**Published:** 30-Nov-2022

## REFERENCES

1. Ashena Z, Nanavaty MA, Bardan AS, Thaker R, Bascaran L. Prophylactic use of nonsteroidal anti-inflammatory drugs after cataract surgery and corneal melt. *J Curr Ophthalmol* 2021;33:485-91.
2. Cabourne E, Lau N, Flanagan D, Nott J, Bloom J, Angunawela R. Severe corneal melting after cataract surgery in patients prescribed topical postoperative NSAIDs and dexamethasone/neomycin combination therapy. *J Cataract Refract Surg* 2020;46:138-42.
3. Chu CJ, Johnston RL, Buscombe C, Sallam AB, Mohamed Q, Yang YC, *et al.* Risk factors and incidence of macular edema after cataract surgery: A database study of 81984 eyes. *Ophthalmology* 2016;123:316-23.
4. Wielders LH, Lambermont VA, Schouten JS, van den Biggelaar FJ, Worthy G, Simons RW, *et al.* Prevention of cystoid macular edema after cataract surgery in nondiabetic and diabetic patients: A systematic review and meta-analysis. *Am J Ophthalmol* 2015;160:968-81.e33.
5. Denniston AK, Chakravarthy U, Zhu H, Lee AY, Crabb DP, Tufail A, *et al.* The UK diabetic retinopathy electronic medical record (UK DR EMR) Users Group, report 2: Real-world data for the impact of cataract surgery on diabetic macular oedema. *Br J Ophthalmol* 2017;101:1673-8.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

## Access this article online

### Quick Response Code:



### Website:

www.jcurrphthalmol.org

### DOI:

10.4103/joco.joco\_107\_22

**How to cite this article:** Shalchi Z, Angunawela R, Hamilton R. Letter to Editor: Prophylactic use of nonsteroidal anti-inflammatory drugs after cataract surgery and corneal melt. *J Curr Ophthalmol* 2022;34:384.

© 2022 Journal of Current Ophthalmology | Published by Wolters Kluwer - Medknow